Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-24T20:12:08.809Z Has data issue: false hasContentIssue false
  • English
  • Français

Understanding the Neurobiology of Comorbidity in Anxiety Disorders

Published online by Cambridge University Press:  07 November 2014

David J. Nutt  and
Dan J. Stein
David J. Nutt*
Affiliation:
Dr. Nutt is professor of psychopharmacology in the Psychopharmacology Unit at the, University of Bristol, United Kingdom
Dan J. Stein
Affiliation:
Dr. Stein is professor and chair of the Department of Psychiatry at the University of Cape Town in south Africa, and is also on the faculty at, Mount Sinai School of Medicine in New York City
*
David J. Nutt, MD, PhD, Psychopharmacology Unit, Dorothy Hodgkin Building, University of Bristol, Bristol, UKBS8 1TD; Tel: 44-0-117-331-3143; Fax: 44-0-117-331-3143; E-mail: david.j.nutt@bristol.ac.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Anxiety and depression are common disorders that frequently co-exist. Both disorders show good response to antidepressants, especially the selective serotonin reuptake inhibitors. Some suggest that these disorders are variants of the same underlying brain pathology. This review examines the similarities and differences between anxiety and depression in terms of the known neurobiological etiologic mechanisms as well as their biological underpinnings and response to treatment. Sufficient and significant differences between these disorders support the view that they are independent entities. Shared abnormalities in the 5HT1A receptor function, for example, may help explain some of the comorbidity.

Type
Research Article
Information
CNS Spectrums , Volume 11 , Issue S12 , 2006 , pp. 13 - 20
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.DeVane, CL, Chiao, E, Franklin, M, Kruep, EJ. Anxiety disorders in the 21st century: status, challenges, opportunities, and comorbidity with depression. Am J Manag Care. 2005;11:S344–S353.Google ScholarPubMed
2.Ninan, PT. Recent perspectives on the diagnosis and treatment of generalized anxiety disorder. Am J Manag Care. 2001;7:S367–S376.Google ScholarPubMed
3.Kessler, RC, Berglund, P, Demler, O, Jin, R, Walters, EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.CrossRefGoogle ScholarPubMed
4.Kessler, RC, Chiu, WT, Demler, O, Walters, EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–627.CrossRefGoogle ScholarPubMed
5.Wittchen, HU, Zhao, S, Kessler, RC, Eaton, WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:355–364.CrossRefGoogle ScholarPubMed
6.Kaufman, J, Charney, D. Comorbidity of mood and anxiety disorders. Depress Anxiety. 2000;12(suppl 1):69–76.3.0.CO;2-K>CrossRefGoogle ScholarPubMed
7.Kraemer, HC, Wilson, KA, Hayward, C. Lifetime prevalence and pseudocomorbidity in psychiatric research. Arch Gen Psychiatry. 2006;63:604–608.CrossRefGoogle ScholarPubMed
8.Miller, LA, Taber, KH, Gabbard, GO, Hurley, RA. Neural underpinnings of fear and its modulation: implications for anxiety disorders. J Neuropsychiatry Clin Neurosci. 2005;17:1–6.CrossRefGoogle ScholarPubMed
9.Davis, M. Are different parts of the extended amygdala involved in fear versus anxiety? Biol Psychiatry. 1998;44:1239–1247.CrossRefGoogle ScholarPubMed
10.Nutt, DJ. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 11):22–27.Google ScholarPubMed
11.Tillfors, M, Furmark, T, Marteinsdottir, I, et al.Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. Am J Psychiatry. 2001;158:1220–1226.CrossRefGoogle ScholarPubMed
12.Veit, R, Flor, H, Erb, M, et al.Brain circuits involved in emotional learning in antisocial behavior and social phobia in humans. Neurosci Lett. 2002;328:233–236.CrossRefGoogle ScholarPubMed
13.Nutt, DJ, Bell, CJ, Malizia, AL. Brain mechanisms of social anxiety disorder. J Clin Psychiatry. 1998;59:4–11.Google ScholarPubMed
14.Kilts, CD, Kelsey, JE, Knight, Bet al.The neural correlates of social anxiety disorder and response to pharmacotherapy. Neuropsychopharmacology. 2006. Mar 8; [Epub ahead of print].Google Scholar
15.Rauch, SL, Savage, CR, Alpert, NM, Fischman, AJ, Jenike, MA. The functional neuroanatomy of anxiety: a study of three disorders using positron emission tomography and symptom provocation. Biol Psychiatry. 1997;42:446–452.CrossRefGoogle ScholarPubMed
16.Whiteside, SP, Port, JD, Abramowitz, JS. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res. 2004;132:69–79.CrossRefGoogle ScholarPubMed
17.Nutt, DJ, Ballenger, JC, Sheehan, D, Wittchen, HU. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol. 2002;5:315–325.CrossRefGoogle ScholarPubMed
18.Carey, PD, Warwick, J, Niehaus, DJ, et al.Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry. 2004;4:30.CrossRefGoogle ScholarPubMed
19.Gorman, JM. New molecular targets for antianxiety interventions. J Clin Psychiatry. 2003;64(suppl 3):28–35.Google ScholarPubMed
20.Westenberg, HG, Liebowitz, MR. Overview of panic and social anxiety disorders. J Clin Psychiatry. 2004;65(suppl 14):22–26.Google ScholarPubMed
21.PP, Roy-Byrne. The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety. J Clin Psychiatry. 2005;66(suppl 2):14–20.Google Scholar
22.Tiihonen, J, Kuikka, J, Rasanen, P, et al.Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry. 1997;2:463–471.CrossRefGoogle ScholarPubMed
23.Malizia, AL, Cunningham, VJ, Bell, CJ, Liddle, PF, Jones, T, Nutt, DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55:715–720.CrossRefGoogle ScholarPubMed
24.Bremner, JD, Innis, RB, White, T, et al.SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry. 2000;47:96–106.CrossRefGoogle ScholarPubMed
25.Bremner, JD, Innis, RB, Southwick, SM, Staib, L, Zoghbi, S, Charney, DS. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. Am J Psychiatry. 2000;157:1120–1126.CrossRefGoogle ScholarPubMed
26.Nutt, DJ, Malizia, AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001;179:390–396.CrossRefGoogle ScholarPubMed
27.Kent, JM, Mathew, SJ, Gorman, JM. Molecular targets in the treatment of anxiety. Biol Psychiatry. 2002;52:1008–1030.CrossRefGoogle ScholarPubMed
28.Millan, MJ. The neurobiology and control of anxious states. Prog Neurobiol. 2003;70:83–244.CrossRefGoogle ScholarPubMed
29.Lesch, KP, Gutknecht, L. Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. Int J Neuropsychopharmacol. 2004;7:381–385.CrossRefGoogle ScholarPubMed
30.Lemonde, S, Turecki, G, Bakish, D, et al.Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003;23:8788–8799.CrossRefGoogle Scholar
31.Hariri, AR, Mattay, VS, Tessitore, A, et al.Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002;297:400–403.CrossRefGoogle ScholarPubMed
32.Furmark, T, Tillfors, M, Garpenstrand, H, et al.Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett. 2004;362:189–192.CrossRefGoogle ScholarPubMed
33.Rothe, C, Gutknecht, L, Freitag, C, et al.Association of a functional 1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. Int J Neuropsychopharmacol. 2004;7:189–192.CrossRefGoogle Scholar
34.Neumeister, A, Bain, E, Nugent, AC, et al.Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci. 2004;24:589–591.CrossRefGoogle ScholarPubMed
35.Nash, JR, Sargent, PA, Rabiner, EA, et al.Altered 5HT1A binding in panic disorder demonstrated by positron emission tomography. Eur Neuropsychopharmacol. 2004;14:S322–S323.CrossRefGoogle Scholar
36.Sargent, PA, Kjaer, KH, Bench, CJ, et al.Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57:174–180.CrossRefGoogle ScholarPubMed
37.Goodman, WK. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry. 2004;65(suppl)13:8–13.Google ScholarPubMed
38.Katzman, M. Venlafaxine in the treatment of anxiety disorders. Expert Rev Neurother. 2004;4:371–381.CrossRefGoogle ScholarPubMed
39.Nutt, DJ, Forshall, S, Bell, C, et al.Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol. 1999;9(suppl 3):S81–S86.CrossRefGoogle ScholarPubMed
40.Vaswani, M, Linda, FK, Ramesh, S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:85–102.CrossRefGoogle ScholarPubMed
41. U.S. Food and Drug Administration. FDA Public Health Advisory: Worsening Depression and Suicidality in Patients Being Treated With Antidepressant. Available at: http://www.fda.gov/CDER/DRUG/antidepressants/AntidepressanstPHA.htm. Accessed August 10, 2006.Google Scholar
42.Hood, SD, Bell, CJ, Nutt, DJ. Acute tryptophan depletion. Part I: rationale and methodology. Aust N Z J Psychiatry. 2005;39:558–564.CrossRefGoogle ScholarPubMed
43.Delgado, PL, Miller, HL, Salomon, RM, et al.Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry. 1999;46:212–220.CrossRefGoogle ScholarPubMed
44.Leyton, M, Young, SN, Blier, P, et al.The effect of tryptophan depletion on mood in medication-free, former patients with major affective disorder. Neuropsychopharmacology. 1997;16:294–297.CrossRefGoogle ScholarPubMed
45.Barr, LC, Goodman, WK, McDougle, CJ, et al.Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994;51:309–317.CrossRefGoogle ScholarPubMed
46.Berney, A, Sookman, D, Leyton, M, Young, SN, Benkelfat, C. Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients. Biol Psychiatry. 2006;853–857.Google Scholar
47.Bell, C, Forshall, S, Adrover, M, et al.Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol. 2002;16:5–14.CrossRefGoogle Scholar
48.Argyropoulos, SV, Hood, SD, Adrover, M, et al.Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry. 2004;56:503–509.CrossRefGoogle ScholarPubMed
49.Bell, CJ, Malizia, AL, Nutt, DJ. The neurobiology of social phobia. Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl 1):S11–S18.CrossRefGoogle ScholarPubMed